Search Result

Results for "

Locomotor activity.

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adrenergic Receptor (3) Amine N-methyltransferase (1) Cannabinoid Receptor (4) Cholinesterase (ChE) (1) DAGL (1) Dopamine Receptor (15) Dopamine Transporter (1) Drug Intermediate (1) Drug Isomer (1) Drug Metabolite (1) EAAT (1) Endogenous Metabolite (2) Environmental Pollutants (2) Fungal (2) GABA Receptor (5) HCN Channel (1) HDAC (1) Histamine Receptor (3) iGluR (2) Interleukin Related (1) Isotope-Labeled Compounds (2) mAChR (2) mGluR (1) Monoamine Oxidase (1) Monoamine Transporter (1) Neuropeptide S Receptor (1) Neuropeptide Y Receptor (1) Opioid Receptor (3) Orexin Receptor (OX Receptor) (3) Phosphodiesterase (PDE) (1) Potassium Channel (1) Reactive Oxygen Species (ROS) (1) Reference Standards (7) Sigma Receptor (5) TNF Receptor (1) Trace Amine-associated Receptor (TAAR) (1) Tyrosinase (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Endocrinology (3) Infection (2) Inflammation/Immunology (4) Metabolic Disease (5) Neurological Disease (52)

By Targets:

5-HT Receptor (3)

Adrenergic Receptor (3)

Amine N-methyltransferase (1)

Cannabinoid Receptor (4)

Cholinesterase (ChE) (1)

DAGL (1)

Dopamine Receptor (15)

Dopamine Transporter (1)

Drug Intermediate (1)

Drug Isomer (1)

Drug Metabolite (1)

EAAT (1)

Endogenous Metabolite (2)

Environmental Pollutants (2)

Fungal (2)

GABA Receptor (5)

HCN Channel (1)

HDAC (1)

Histamine Receptor (3)

iGluR (2)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

mAChR (2)

mGluR (1)

Monoamine Oxidase (1)

Monoamine Transporter (1)

Neuropeptide S Receptor (1)

Neuropeptide Y Receptor (1)

Opioid Receptor (3)

Orexin Receptor (OX Receptor) (3)

Phosphodiesterase (PDE) (1)

Potassium Channel (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (7)

Sigma Receptor (5)

TNF Receptor (1)

Trace Amine-associated Receptor (TAAR) (1)

Tyrosinase (2)

By Research Areas:

Cancer (2)

Cardiovascular Disease (1)

Endocrinology (3)

Infection (2)

Inflammation/Immunology (4)

Metabolic Disease (5)

Neurological Disease (52)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10895

SB-334867 Maximum Cited Publications 10 Publications Verification SB 334867A	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
SB-334867 (SB 334867A) is an excellent,selective and blood-brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pK_b=7.4), 100-fold over 5-HT_2B, 5-HT_2C with pK_i values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .

HY-W011689

6PPD 1 Publications Verification	Reactive Oxygen Species (ROS)	Others
6PPD is a rubber antioxidant that scavenges ozone and forms nitro radicals. Exposure to 6PPD reduces the hatching rate, impairs spontaneous locomotor activity, shortens body length and causes malformations in zebrafish embryos. 6PPD also induces oxidative stress in zebrafish embryos .

HY-W013150

Alpidem	GABA Receptor	Neurological Disease
Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC₅₀ of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC₅₀ of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions .

HY-15451

MDA 19 2 Publications Verification BZO-HEXOXIZID	Cannabinoid Receptor	Neurological Disease
MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a K_i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .

HY-10895A

SB-334867 free base Maximum Cited Publications 10 Publications Verification SB334867A free base	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
SB-334867 free base (SB334867A free base) is an excellent, selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pK_b=7.4), 100-fold over 5-HT_2B, 5-HT_2C with pK_i values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .

HY-117771

DO34 5 Publications Verification	DAGL	Neurological Disease Metabolic Disease
DO34 is a selective DAGL inhibitor, with an IC₅₀ of 6 nM for DAGLα conversion of SAG to 2-AG. DO34 blocks de novo 2-AG synthesis, and suppresses tonic CB₁ receptor activation. DO34 blocks depolarization-induced suppression of excitation and inhibition in the cerebellum and hippocampus. DO34 regulates feeding behavior and locomotor activity in mice. DO34 abolishes AM251-mediated enhancement of parallel fiber-evoked excitatory postsynaptic currents in cerebellar slices from MAGL global knockout mice. DO34 can be used for the research of energy balance disorder and neuroinflammation .

HY-A0277

Cyproconazole	Environmental Pollutants Fungal	Others
Cyproconazole is a triazole fungicide used to protect crops, fruits and vegetables against a wide range of fungal pathogens. Cyproconazole can cause hepatocellular adenomas and carcinomas in CD-1 mice. Cyproconazole also exhibits low toxicity to zebrafish embryos and affects locomotor activity .

HY-172550

MS7710	HCN Channel	Neurological Disease
MS7710 is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel inhibitor with blood-brain barrier permeability and an excellent brain/plasma concentration ratio. MS7710 inhibits HCN channel-mediated I_h current, and reduces the firing frequency and burst activity of dopaminergic neurons in the ventral tegmental area. MS7710 ameliorates chronic social defeat stress-induced deficits in social interaction and impairments in reward-related cognitive flexibility in mice. MS7710 exerts only limited effects on ventral tegmental area dopaminergic neuron activity, social interaction, exploratory behavior, locomotor activity or sucrose preference in control mice. MS7710 is applicable to the research of major depressive disorder .

HY-113357

m-Coumaric acid	Endogenous Metabolite	Neurological Disease Metabolic Disease Inflammation/Immunology
m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .

HY-171844

CX1739	iGluR	Neurological Disease Inflammation/Immunology
CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury .

HY-168773

(R)-AS-1	EAAT	Neurological Disease
(R)-AS-1 is a selective positive allosteric modulator of the excitatory amino acid transporter 2 (EAAT2), with an EC₅₀ of 11 nM. (R)-AS-1 (at doses of 60 and 90 mg/kg) increases spontaneous locomotor activity in mice. Additionally, it demonstrates anticonvulsant activity in mouse models of seizures induced by maximal electroshock (MES), pentylenetetrazole (PTZ), or electrical stimuli (32 or 44 mA), with ED₅₀s of 66.3, 36.3, 15.6, and 41.6 mg/kg, respectively. (R)-AS-1 can be used in neurological disease research .

HY-118301

ADX71441	GABA Receptor 5-HT Receptor	Neurological Disease
ADX71441 is an orally active, blood-brain barrier penetrant positive allosteric modulator of GABA_B receptor. ADX71441 potentiates the activity of endogenous GABA at GABA_B receptor, with an EC₅₀ of 96 nM. ADX71441 functionally inhibits adenosine transporters and 5-HT_2B receptor. ADX71441 produces anxiolytic-like, analgesic, muscle relaxant, hypothermic and overactive bladder inhibitory effects, reduces acute locomotor activity levels, decreases voluntary intake of alcohol and saccharin, attenuates stress-induced neuronal activation, and exhibits anti-hyperalgesic activity .

HY-P1329A

CTOP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .

HY-108510

Rimcazole dihydrochloride BW 234U dihydrochloride	Sigma Receptor Dopamine Receptor	Neurological Disease Cancer
Rimcazole (BW 234U) dihydrochloride is a carbazole derivative that acts in part as a sigma (σ) receptor antagonist. Rimcazole dihydrochloride also binds with moderate affinity to the dopamine transporter and inhibit dopamine uptake. Rimcazole dihydrochloride can reduce locomotor activity and sensitization. Rimcazole dihydrochloride also can be used for the research of cancer .

HY-W015616

Benzylacetone 4-Penylbutan-2-one	Environmental Pollutants Tyrosinase	Infection Metabolic Disease
Benzylacetone (4-Penylbutan-2-one) is an aromatic compound. Benzylacetone is a mushroom tyrosinase inhibitor with an IC₅₀ of 2.8 mM, a K_i of 1.25 mM for monophenolase and an IC₅₀ of 0.6 mM, a K_i of 0.39 mM for diphenolase. Benzylacetone inhibits free mushroom tyrosinase and enzyme-substrate complex. Benzylacetone acts as an appetite enhancer via olfactory stimulation, reduces spontaneous locomotor activity, induces weight gain. Benzylacetone exhibits repellent, fumigant, and contact toxicity against Tribolium castaneum adults .

HY-101102

7-Hydroxy-DPAT hydrobromide	Dopamine Receptor	Neurological Disease
7-Hydroxy-DPAT hydrobromide is a selective D3 dopamine receptor agonist, exhibiting significant pharmacological activity in modulating locomotor behavior and dopamine metabolism within the brain.

HY-145454

(R)-Preclamol (+)-3-PPP	Dopamine Receptor	Neurological Disease
(R)-Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. (R)-Preclamol inhibits the locomotor activity of mice and rats in low doses .

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .

HY-P10405A

TAT-D1 peptide acetate	Dopamine Receptor	Neurological Disease
TAT-D1 peptide acetate is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide acetate disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide acetate produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide acetate can be used in the research of psychostimulant addiction, depression and anxiety disorders .

HY-A0277R

Cyproconazole (Standard)	Reference Standards Fungal	Others
Cyproconazole (Standard) is the analytical standard of Cyproconazole. This product is intended for research and analytical applications. Cyproconazole is a triazole fungicide used to protect crops, fruits and vegetables against a wide range of fungal pathogens. Cyproconazole can cause hepatocellular adenomas and carcinomas in CD-1 mice. Cyproconazole also exhibits low toxicity to zebrafish embryos and affects locomotor activity .

HY-172587

CB1R Allosteric modulator 5	Cannabinoid Receptor	Neurological Disease
CB1R Allosteric modulator 5 (compound 3) is a selective, and blood-brain barrier (BBB) permeable Cannabinoid receptor type 1 allosteric modulator with a pIC₅₀ of 6.89. CB1R Allosteric modulator 5 attenuates both cocaine-seeking behavior specific to cue-induced reinstatement and cocaine-induced behavioral sensitization without altering locomotor activity .

HY-113357R

m-Coumaric acid (Standard)	Reference Standards Endogenous Metabolite	Neurological Disease Inflammation/Immunology
m-Coumaric acid (Standard) is the analytical standard of m-Coumaric acid. This product is intended for research and analytical applications. m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .

HY-107055

RTI 336	Dopamine Transporter	Neurological Disease
RTI 336 is a phenyltropane analog, as well as a potent and selective dopamine transporter (DAT) inhibitor. RTI 336 inhibits addictive agent induced locomotor activity and self-administration in Lewis rats. RTI 336 exhibits inhibitory effects depending on inherent NAc DAT levels .

HY-P10405

TAT-D1 peptide	Dopamine Receptor	Neurological Disease
TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders .

HY-134015

7-Hydroxy-DPAT 7-OH-DPAT	Dopamine Receptor	Neurological Disease
7-Hydroxy-DPAT (7-OH-DPAT) is a selective D3 dopamine receptor agonist. 7-Hydroxy-DPAT exhibits significant pharmacological activity in modulating locomotor behavior and dopamine metabolism within the brain. 7-Hydroxy-DPAT can be used for the research of neurological disease .

HY-160718

Adrogolide ABT-431; DAS-431	Dopamine Receptor	Neurological Disease
Adrogolide is an A-86929 (HY-171472) prodrug and dopamine D₁ receptor agonist. Adrogolide is converted rapidly in plasma to A-86929. Adrogolide improves behavioral disability and locomotor activity scores. Adrogolide can also attenuate the ability of Cocaine to induce Cocaine-seeking behavior. Adrogolide can be used in the research of Parkinson's disease .

HY-A0139

Thiothixene NSC 108165; Navan; Navane	Sigma Receptor mAChR Histamine Receptor Dopamine Receptor Adrenergic Receptor	Others
Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.

HY-170654

Opioid receptor antagonist 1	Opioid Receptor	Neurological Disease
Opioid receptor antagonist 1 (Compound 10) is an Orvinol (HY-D0168)-based opioid receptor antagonist. Opioid receptor antagonist 1 has antagonistic activity to the analgesic properties of Morphine .

HY-105637

Cropropamide Propylbutamide	Drug Intermediate	Neurological Disease
Cropropamide is a component of the respiratory stimulant Prethamide. Cropropamide increases locomotor activity in rats .

HY-123440

S3608	Dopamine Receptor	Neurological Disease
S3608 is an atypical dopamine agonist. S3608 dose dependently increase locomotor activity (LA) in rats .

HY-145454A

Preclamol (-)-3-PPP	Dopamine Receptor	Neurological Disease
Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. Preclamol inhibits the locomotor activity of mice and rats in low doses .

HY-168365

(±)-Pellotine hydrochloride	Drug Isomer	Neurological Disease
(±)-Pellotine hydrochloride (Compound 2) is an alkaloid, which is found in L. diffusa and L. fricii. (±)-Pellotine hydrochloride decreases locomotor activity and the amount of rapid eye movement (REM) sleep in mice .

HY-118402

PD 119819	Dopamine Receptor	Neurological Disease
PD 119819 is a highly selective benzopyran-4-one brain dopamine autoreceptor agonist. PD 119819, a heterocyclic piperazine, inhibits spontaneous locomotor activity and brain dopamine synthesis .

HY-121775

PF-00217830	Dopamine Receptor	Neurological Disease
F-00217830 is an agonist ofDopamine D2 receptor. PF-00217830 inhibits of spontaneous locomotor activity and 2,5-dimethoxy-4-iodoamphetamine-induced head twitches in rats .

HY-118461

PD 120697	Dopamine Receptor	Neurological Disease
PD 120697 is an orally active dopamine (DA) agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression .

HY-14222

UMB24	Sigma Receptor	Neurological Disease
UMB24 is a potent antagonist of σ2 receptor, with K_i values of 170 nM anf 322 nM for σ2 receptor and σ1 receptor, respectively. UMB24 attenuats cocaine-induced convulsions and locomotor activity, but not lethality .

HY-P1438A

Neuropeptide S(Rat) TFA	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide S(Rat) TFA is a potent endogenous neuropeptide S receptor (NSPR) agonist (EC₅₀=3.2 nM). Neuropeptide S(Rat) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Rat) TFA also reduces anxiety-like behavior in mice.

HY-113981

LY459477	mGluR	Neurological Disease
LY459477 is a potent, selective and orally active metabotropic glutamate 2/3 receptor (mGluR2/3) agonist. LY459477 can effectively suppress Phencyclidine-evoked locomotor activity at doses that do not impair neuromuscular coordination. LY459477 can be used for the research of neurological disease .

HY-15451R

MDA 19 (Standard) BZO-HEXOXIZID (Standard)	Reference Standards Cannabinoid Receptor	Neurological Disease
MDA 19 (Standard) is the analytical standard of MDA 19. This product is intended for research and analytical applications. MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .

HY-P1437A

Neuropeptide S (Mouse) TFA	Neuropeptide S Receptor	Neurological Disease
Neuropeptide S(Mouse) TFA is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC₅₀=3 nM). Neuropeptide S(Mouse) TFA induces mobilization of intracellular Ca ²⁺. Neuropeptide S(Mouse) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Mouse) TFA also reduces anxiety-like behavior in mice.

HY-168334

5-HT2C agonist-4	5-HT Receptor	Neurological Disease
5-HT2C agonist-4 (Compound 3i) is an agonist for 5-HT2C receptor with an EC₅₀ of 5.7 nM. 5-HT2C agonist-4 reduces locomotor activity in the zebrafish larval model .

HY-103496

U-90042	GABA Receptor	Neurological Disease
U-90042 is a gamma-aminobutyric acidA receptor agonist of α1, α3 and α6 subtypes with K_i values of 7.8 nM, 9.5 nM and 11.0 nM, respectively. U-90042 suppresses locomotor activity and impairs rotarod performance in mice. U-90042 produces sedation and ataxia and prolongs sleeping time in mice, rats and monkeys. U-90042 can be used as a sedative and hypnotic agent .

HY-10895R

SB-334867 (Standard) SB 334867A (Standard)	Orexin Receptor (OX Receptor) Reference Standards	Neurological Disease Endocrinology
SB-334867 (Standard) is the analytical standard of SB-334867. This product is intended for research and analytical applications. SB-334867 (SB 334867A) is an excellent,selective and blood-brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .

HY-169156

HDAC6-IN-49	HDAC Monoamine Oxidase Cholinesterase (ChE) Histamine Receptor 5-HT Receptor	Neurological Disease
HDAC6-IN-49 (Compound 3) is an inhibitor for HDAC with IC₅₀ of 0.012 and 0.735 μM for HDAC6 and HDAC1. HDAC6-IN-49 also exhibits inhibitory activities against MAO-B, cholinesterase (ChE), histamine receptor (H3R) and serotonin 6 receptor (5-HT6R). HDAC6-IN-49 exhibits neuroprotective efficacy on SH-SY5Y cell. HDAC6-IN-49 improves cognitive function and locomotor ability in Drosophila Parkinson's disease models and in C. elegans Alzheimer's disease models .

HY-W013150R

Alpidem (Standard)	Reference Standards GABA Receptor	Neurological Disease
Alpidem (Standard) is the analytical standard of Alpidem (HY-W013150). This product is intended for research and analytical applications. Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC₅₀ of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC₅₀ of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.

HY-W013150S

Alpidem-d14	Isotope-Labeled Compounds GABA Receptor	Neurological Disease
Alpidem-d₁₄ is the deuterium labeled Alpidem (HY-W013150) . Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC₅₀ of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC₅₀ of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.

HY-W748758

(Z)-Thiothixene-d8 NSC 108165-d₈; Navan-d₈; Navane-d₈	Isotope-Labeled Compounds Dopamine Receptor Histamine Receptor mAChR Adrenergic Receptor Sigma Receptor	Others
(Z)-Thiothixene-d₈ (NSC 108165-d₈; Navan-d₈; Navane-d₈) is the deuterium labeled Thiothixene (HY-A0139). Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.

HY-118010B

(-)-Norfenfluramine l-Norfenfluramine	Drug Metabolite	Neurological Disease
(-)-Norfenfluramine (l-Norfenfluramine) is a Fenfluramine metabolite. (-)-Norfenfluramine effectively counteracts the zebrafish abnormal locomotor activity. (-)-Norfenfluramine can be used in epilepsy research .

HY-120291

ASP9436	Phosphodiesterase (PDE)	Neurological Disease
ASP9436 is an orally active and blood-brain barrier permeable PDE10A inhibitor with an IC₅₀ of 8 nM against human PDE10A. ASP9436 attenuates locomotor activity in mouse hyperactivity models and ameliorates visual recognition memory impairment in neonatal mice. ASP9436 is applicable to research related to schizophrenia .

HY-183428

LK00764	Trace Amine-associated Receptor (TAAR)	Neurological Disease
LK00764 is a TAAR1 agonist with an EC₅₀ of 4 nM. LK00764 alleviates Dizocilpine (HY-15084B)-induced hyperlocomotion, reduces vertical locomotor activity, attenuates spontaneous hyperlocomotion in dopamine transporter knockout rats, and inhibits stress-induced hyperthermia in rats. LK00764 can be used for the research of schizophrenia .

Cat. No.	Product Name	Target	Research Area

HY-P3538

Corticotropin-releasing factor (Sheep) CRH (Sheep)	Peptides	Neurological Disease
Corticotropin-releasing factor (CRH) (Sheep) is a brain-penetrant hypothalamic releasing factor and a peptide hormone with analgesic and arousal-inducing activity. Corticotropin-releasing factor (Sheep) mediates stress effects, including stress-induced analgesia. Corticotropin-releasing factor (Sheep) increases wakefulness, reduces slow wave sleep, alters EEG frequency content, stimulates ACTH and β-endorphin release, activates locomotor activity. Corticotropin-releasing factor (Sheep) can be used for the research of neurological disease .

HY-P1329A

CTOP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .

HY-P10405A

TAT-D1 peptide acetate	Dopamine Receptor	Neurological Disease
TAT-D1 peptide acetate is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide acetate disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide acetate produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide acetate can be used in the research of psychostimulant addiction, depression and anxiety disorders .

HY-P3568

Adipokinetic hormone (Gryllus bimaculatus) Grybi-AKH	Peptides	Metabolic Disease
Adipokinetic hormone Gryllus bimaculatus (Grybi-AKH) is an adipokinetic hormone that regulates energy homeostasis in insects by mobilizing lipid and carbohydrate from the fat body. Adipokinetic hormone Gryllus bimaculatus stimulates the locomotor activity of the two-spotted cricket. Adipokinetic hormone Gryllus bimaculatus can also be used in studies to regulate body weight, induce weight loss and alleviate glycogen storage disorders in humans .

HY-P10405

TAT-D1 peptide	Dopamine Receptor	Neurological Disease
TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders .

HY-P1438A

Neuropeptide S(Rat) TFA	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide S(Rat) TFA is a potent endogenous neuropeptide S receptor (NSPR) agonist (EC₅₀=3.2 nM). Neuropeptide S(Rat) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Rat) TFA also reduces anxiety-like behavior in mice.

HY-P1437A

Neuropeptide S (Mouse) TFA	Neuropeptide S Receptor	Neurological Disease
Neuropeptide S(Mouse) TFA is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC₅₀=3 nM). Neuropeptide S(Mouse) TFA induces mobilization of intracellular Ca ²⁺. Neuropeptide S(Mouse) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Mouse) TFA also reduces anxiety-like behavior in mice.

HY-P11105

Short neuropeptide F	Peptides	Neurological Disease
Short neuropeptide F is an insect neurohormone involved in regulating insect locomotor activity and circadian rhythm .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113357

m-Coumaric acid	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Phenols Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .

HY-W015616

Benzylacetone 4-Penylbutan-2-one	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Thymelaeaceae Metabolic Disease Plants Aquilaria sinensis (Lour.) Spreng. Disease Research Fields Source Classification	Environmental Pollutants Tyrosinase
Benzylacetone (4-Penylbutan-2-one) is an aromatic compound. Benzylacetone is a mushroom tyrosinase inhibitor with an IC₅₀ of 2.8 mM, a K_i of 1.25 mM for monophenolase and an IC₅₀ of 0.6 mM, a K_i of 0.39 mM for diphenolase. Benzylacetone inhibits free mushroom tyrosinase and enzyme-substrate complex. Benzylacetone acts as an appetite enhancer via olfactory stimulation, reduces spontaneous locomotor activity, induces weight gain. Benzylacetone exhibits repellent, fumigant, and contact toxicity against Tribolium castaneum adults .

HY-113357R

m-Coumaric acid (Standard)	Structural Classification Monophenols Microorganisms Ketones, Aldehydes, Acids Phenols Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
m-Coumaric acid (Standard) is the analytical standard of m-Coumaric acid. This product is intended for research and analytical applications. m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .

HY-N17853

Siaresinolic acid	Structural Classification Terpenoids Rubiaceae Sabicea grisea Cham. & Schltdl. Plants Pentacyclic Triterpenoids Source Classification	Potassium Channel TNF Receptor Interleukin Related
Siaresinolic acid is a compound found in the leaves of Sabicea grisea. Siaresinolic acid shows antinociceptive and anti-inflammatory activity. Siaresinolic acid reduces nociceptive behavior by ATP-dependent potassium channel, inhibits leukocyte influx, plasma leakage, and proinflammatory mediator (TNF-α, IL-1β) production. Siaresinolic acid does not induce cytotoxicity in murine macrophages, alter locomotor activity at high doses. Siaresinolic acid can be used for the research of pleurisy and pain .

HY-W015616R

Benzylacetone (Standard) 4-Penylbutan-2-one (Standard)	Structural Classification Ketones, Aldehydes, Acids Thymelaeaceae Plants Aquilaria sinensis (Lour.) Spreng. Source Classification	Tyrosinase Reference Standards
Benzylacetone (4-Penylbutan-2-one) (Standard) is the analytical standard of Benzylacetone (HY-W015616). This product is intended for research and analytical applications. Benzylacetone is an aromatic compound. Benzylacetone is a mushroom tyrosinase inhibitor with an IC₅₀ of 2.8 mM, a K_i of 1.25 mM for monophenolase and an IC₅₀ of 0.6 mM, a K_i of 0.39 mM for diphenolase. Benzylacetone inhibits free mushroom tyrosinase and enzyme-substrate complex. Benzylacetone acts as an appetite enhancer via olfactory stimulation, reduces spontaneous locomotor activity, induces weight gain. Benzylacetone exhibits repellent, fumigant, and contact toxicity against Tribolium castaneum adults .

Cat. No.	Product Name	Chemical Structure

HY-W013150S

Alpidem-d14

Alpidem-d₁₄ is the deuterium labeled Alpidem (HY-W013150) . Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC₅₀ of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC₅₀ of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions.

HY-W748758

(Z)-Thiothixene-d8

(Z)-Thiothixene-d₈ (NSC 108165-d₈; Navan-d₈; Navane-d₈) is the deuterium labeled Thiothixene (HY-A0139). Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks